ANDA 77027, held by Teva. Cilostazol.
As of Nov 16, 2026, ANDA 77027 (Cilostazol), held by Teva, was first approved by FDA on Nov 24, 2004, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 24, 2004 | Original application | Approved | None posted |
| Cilostazol50MG · tablet;oral | Cilostazol | Rx |
| Cilostazol100MG · tablet;oral | Cilostazol | Rx |
| Dec 18, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Apr 4, 2016 | Supplement 17Labeling · Standard review | Approved | None posted |
| Apr 4, 2016 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 31, 2014 | Supplement 10Labeling | Approved | None posted |
| Nov 6, 2014 | Supplement 8Manufacturing | Approved | None posted |
| Sep 23, 2014 | Supplement 7Labeling | Approved | None posted |
| Mar 9, 2012 | Supplement 13Labeling | Approved | None posted |
| Jun 27, 2008 | Supplement 5Labeling | Approved | None posted |
| Dec 7, 2006 | Supplement 3Labeling | Approved | None posted |
| May 8, 2006 | Supplement 2Labeling | Approved | None posted |
| Nov 24, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters